A brief review of computer-assisted approaches to rational design of peptide vaccines

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Nandy, Ashesh ^a   Basak, Subhash C ^b  

^a Centre for Interdisciplinary Research and Education   (India)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

Author keywords

Alignment free analysis; Chikungunya; Computer assisted vaccine development; Dengue; Epitopes; Peptide vaccines; Rational peptide vaccine design; Rotavirus; Sequence descriptors; Web based approaches; Zika virus

Indexed keywords

ANTIGEN; CD45 ANTIGEN; EPITOPE; INACTIVATED VACCINE; LIVE VACCINE; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MUCIN 1; NAKED DNA; PEPTIDE; PEPTIDE VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; SUBUNIT VACCINE;

AMINO ACID SEQUENCE; ANTIGENICITY; BIOINFORMATICS; CHEMOTHERAPY; COMPUTER AIDED DESIGN; COMPUTER MODEL; CRYSTAL STRUCTURE; DATA BASE; DNA SEQUENCE; DRUG DESIGN; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DOCKING; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYLOGENY; PROTEIN STRUCTURE; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECOMBINANT DNA TECHNOLOGY; REVIEW; SEQUENCE ANALYSIS; VACCINE PRODUCTION; VIRUS GENOME; VIRUS INFECTION; VIRUS TRANSMISSION; CHEMISTRY; DRUG DEVELOPMENT; IMMUNOLOGY; PROCEDURES;

DRUG DISCOVERY; MOLECULAR DOCKING SIMULATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES, SUBUNIT;

EID: 84965028138     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050666     Document Type: Review

References (66)

1. Stanaway, J. D.; Shepard, D. S.; Undurraga, E. A.; Halasa, Y. A.; Coffeng, L. E.; Brady, O. J.; Hay, S. I.; Bedi, N.; Bensenor, I. M.; Castañeda-Orjuela, C. A.; et al. The global burden of dengue: An analysis from the Global Burden of Disease Study 2013. Lancet Infect. Dis. 2016. [CrossRef]
2. World Health Organization. Global networks for surveillance of rotavirus gastroenteritis, 2001-2008. Wkly. Epidemiol. Rec. 2008, 83, 421-428.
3. World Health Organization. Influenza (Seasonal). Fact Sheet No. 211. March 2014. Available online: http: //www. who. int/mediacentre/factsheets/fs211/en/ (accessed on 16 March 2016).
4. Gorbalenya, A. E.; Snijder, E. J.; Spaan, W. J. Severe acute respiratory syndrome coronavirus phylogeny: Toward consensus. J. Virol. 2004, 78, 7863-7866. [CrossRef] [PubMed]
5. World Health Organization. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). June 2015. Available online: http: //www. who. int/mediacentre/factsheets/mers-cov/en/ (accessed on 18 March 2016).
6. World Health Organization. Ebola Virus Disease Outbreak. March 2016. Available online: http: //www. who. int/csr/disease/ebola/en/ (accessed on 18 March 2016).
7. PR Tufts CSDD 2014 Cost Study. Cost to Develop and Win Marketing Approval for a New Drug Is $2. 6 Billion. Available online: http: //csdd. tufts. edu/news/complete_story/pr_tufts_csdd_2014_cost_study (accessed on 9 January 2015).
8. Chit, A.; Parker, J.; Halperin, S. A.; Papadimitropoulos, M.; Krahn, M.; Grootendorst, P. Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines. Vaccine 2014, 32, 3336-3340. [CrossRef] [PubMed]
9. Wong, S.-S.; Webby, R. J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476-492. [CrossRef] [PubMed]
10. Shimizu, H.; Thorley, B.; Paladin, F. J.; Brussen, K. A.; Stambos, V.; Yuen, L.; Utama, A.; Tano, Y.; Arita, M.; Yoshida, H.; et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 2004, 78, 13512-13521. [CrossRef] [PubMed]
11. Chroboczek, J.; Szurgot, I.; Szolajska, E. Virus-like particles as vaccine. Acta Biochim. Polonica 2014, 61, 531-539.
12. Poland, G. A.; Whitaker, J. A.; Poland, C. M.; Ovsyannikova, I. G.; Kennedy, R. B. Vaccinology in the third millennium: Scientific and social challenges. Curr. Opin. Virol. 2016, 17, 116-125. [CrossRef] [PubMed]
13. Poland, G. A.; Kennedy, R. B.; Ovsyannikova, I. G. Vaccinomics and personalized vaccinology: Is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog. 2011, 7, e1002344. [CrossRef] [PubMed]
14. Purcell, A. W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. 2007, 6, 404-414. [CrossRef] [PubMed]
15. Langeveld, J. P. M.; Casal, J. I.; Osterhaus, A. D. M. E.; Cortes, E.; de Swart, R.; Vela, C.; Dalsgaard, K.; Puijk, W. C.; Schaaper, W. M. M.; Meloen, R. H. First peptide vaccine providing protection against viral infection in the target animal: Studies of canine parvovirus in dogs. J. Virol. 1994, 68, 4506-4513. [PubMed]
16. Wang, R.; Charoenvit, Y.; Corradin, G.; Porrozzi, R.; Hunter, R. L.; Glenn, G.; Alving, C. R.; Church, P.; Hoffman, S. L. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 1995, 154, 2764-2793.
17. Monso, M.; Tarradas, J.; de la Torre, B. G.; Sobrino, F.; Ganges, L.; Andreu, D. Peptide vaccine candidates against classical swine fever virus: T cell and neutralizing antibody responses of dendrimers displaying E2 and NS2-3 epitopes. J. Pept. Sci. 2011, 17, 24-31. [CrossRef] [PubMed]
18. ClinicalTrials gov. Available online: https: //clinicaltrials. gov/ct2/results?term=peptide+vaccines&pg=2 (accessed on 13 March 2016).
19. Moisa, A. A.; Kolesanova, E. F. Synthetic peptide vaccines. In Insight and Control of Infectious Disease in Global Scenario; Roy, P., Ed.; ISBN: 978-953-51-0319-6; InTech: Rijeka, Croatia, 2012.
20. NIAID. Available online: https: //www. niaid. nih. gov/topics/zika/Pages/default. aspx (accessed on 16 March 2016).
21. Brossart, P.; Wirths, S.; Stuhler, G.; Reichardt, V. L.; Kanz, L.; Brugger, W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96, 3102-3108. [PubMed]
22. Ludewig, B.; Barchiesi, F.; Pericin, M.; Zinkernagel, R. M.; Hengartner, H.; Schwendener, R. A. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 2001, 19, 23-32. [CrossRef]
23. Liao, S.-J.; Deng, D.-R.; Zeng, D.; Ma, D. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo. J. Huazhong Univ. Sci. Technol. 2013, 33, 735-742. [CrossRef] [PubMed]
24. Rojas-Caraballo, J.; López-Abán, J.; Pérez del Villar, L.; Vizcaíno, C.; Vicente, B.; Fernández-Soto, P.; del Olmo, E.; Patarroyo, M. A.; Muro, A. In vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by fasciola hepatica-derived synthetic peptides containing B-and T-cell epitopes. PLoS ONE 2014, 9, e105323.
25. Suzuki, H.; Fukuhara, M.; Yamaura, T.; Mutoh, S.; Okabe, N.; Yaginuma, H.; Hasegawa, T.; Yonechi, A.; Osugi, J.; Hoshino, M.; et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J. Trans. Med. 2013, 11, 97. [CrossRef] [PubMed]
26. IEDB Analysis Resource. Available online: http: //tools. immuneepitope. org/bcell/ (accessed on 10 March 2016).
27. Kolaskar, A. S.; Tongaonkar, P. C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276, 172-174. [CrossRef]
28. Islam, R.; Sakib, M. S.; Zaman, A. A computational assay to design an epitope-based peptide vaccine against chikungunya virus. Future Virol. 2012, 7, 1029-1042. [CrossRef]
29. Poland, G. A.; Ovsyannikova, I. G.; Jacobson, R. M. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009, 10, 837-852. [CrossRef] [PubMed]
30. Rappuoli, R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19, 2688-2691. [CrossRef]
31. Barocchi, M. A.; Censini, S.; Rappuoli, R. Vaccines in the era of genomics: The pneumococcal challenge. Vaccine 2007, 25, 2963-2973. [CrossRef] [PubMed]
32. Varghese, J. N. Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev. Res. 1999, 46, 176-196. [CrossRef]
33. Hardy, L. W.; Malikayil, A. The impact of structure-guided drug design on clinical agents. Curr. Drug Discov. 2003, 11, 15-20.
34. Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults. Available online: https: //clinicaltrials. gov/ct2/show/NCT02691130?term=influenza+ AND+peptide+vaccines&rank=4 (accessed on 13 March 2016).
35. Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01. 1). Available online: https: //clinicaltrials. gov/ct2/show/NCT01677676?term=influenza+AND+ peptide+vaccines&rank=9 (accessed on 13 March 2016).
36. HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease (HIV-BIS). Available online: https: //clinicaltrials. gov/ct2/show/NCT01141205?term=sers+peptide+vaccine&rank=12 (accessed on 13 March 2016).
37. Vaccine Therapy and Cyclophosphamide in Treating Patients with Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Available online: https: //clinicaltrials. gov/ct2/show/ NCT01606241?term=cancer+and+peptide+vaccines&rank=4 (accessed on 13 March 2016).
38. Vaccine Therapy in Treating Patients with Metastatic Cancer. Available online: https: //clinicaltrials. gov/ ct2/show/NCT00020267?term=cancer+and+peptide+vaccines&rank=16 (accessed on 13 March 2016).
39. Singluff, C. L. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 2011, 17, 343-350. [CrossRef] [PubMed]
40. Huber, S. R.; van Beek, J.; de Jonge, J.; Luytjes, W.; van Baarle, D. T cell responses to viral infections-Opportunities for peptide vaccination. Front. Immunol. 2014, 5, 1-12.
41. Li, W.; Joshi, M. D.; Singhania, S.; Ramsey, K. H.; Murthy, A. K. Peptide vaccine: Progress and challenges. Vaccines 2014, 2, 515-536. [CrossRef] [PubMed]
42. Sirskyj, D.; Diaz-Mitoma, F.; Golshani, A.; Kumar, A.; Azizi, A. Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol. Cell Biol. 2011, 89, 81-89. [CrossRef] [PubMed]
43. Sobolev, B. N.; Olenina, L. V.; Kolesanova, E. F.; Poroikov, V. V.; Archakov, A. I. Computer design of vaccines: Approaches, software tools and informational resources. Curr. Comp. Aided Drug Des. 2005, 1, 207-222. [CrossRef]
44. Tomar, N.; de, R. K. Immunoinformatics: An integrated study. Immunology 2010, 131, 153-168. [CrossRef] [PubMed]
45. Basak, S. C.; Nandy, A. Computer-assisted approaches as decision support systems in the overall strategy of combating emerging diseases: Some comments regarding drug design, vaccinomics, and genomic surveillance of the Zika virus. Curr. Comput.-Aided Drug Des. 2016, 12, 1-3. [CrossRef]
46. Doytchinova, I. A.; Flower, D. R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007, 8. [CrossRef] [PubMed]
47. Immune Epitope Database and Analysis Resource. Available online: http: //www. iedb. org/home_v2. php? Clear=Clear# (accessed on 15 March 2016).
48. ABCpred. Available online: http: //www. imtech. res. in/raghava/abcpred/ (accessed on 15 March 2016).
49. Oyarzun, P.; Ellis, J. J.; Bodén, M.; Kobe, B. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. BMC Bioinform. 2013, 14. [CrossRef] [PubMed]
50. Oany, A. R.; Emran, A.-A.; Jyoti, T. P. Design of an epitope-based peptide vaccine against spike protein of human coronavirus: An in silico approach. Drug Des. Dev. Ther. 2014, 8, 1139-1149. [CrossRef] [PubMed]
51. NetCTL 1. 2 Server. Available online: http: //www. cbs. dtu. dk/services/NetCTL/ (accessed on 16 March 2016).
52. Chakraborty, S.; Chakravorty, R.; Ahmed, M.; Rahman, A.; Waise, T. M. Z.; Hassan, F.; Rahman, M.; Shamsuzzaman, S. A computational approach for identification of epitopes in dengue virus envelope protein: A step towards designing a universal dengue vaccine targeting endemic regions. In Silico Biol. 2010, 10, 235-246. [PubMed]
53. Gomase, V. S.; Kale, K. V.; Chikhale, N. J.; Changbhale, S. S. Prediction of MHC binding peptides and epitopes from alfalfa mosaic virus. Curr. Drug Discov. Technol. 2007, 4, 117-215. [CrossRef] [PubMed]
54. Gomase, V. S.; Kale, K. V. Prediction of MHC binder for fragment based viral peptide vaccines from cabbage leaf curl virus. Gene Ther. Mol. Biol. 2008, 12, 83-86.
55. Ghosh, A.; Nandy, A.; Nandy, P.; Gute, B. D.; Basak, S. C. Computational study of dispersion and extent of mutated and duplicated sequences of the H5N1 influenza neuraminidase over the period 1997-2008. J. Chem. Inf. Model. 2009, 49, 2627-2638. [CrossRef] [PubMed]
56. Nandy, A.; Basak, S. C. Prognosis of possible reassortments in recent H5N2 epidemic influenza in USA: Implications for computer-assisted surveillance as well as drug/vaccine design. Curr. Comput. Aided Drug. Des. 2015, 11, 110-116. [CrossRef] [PubMed]
57. Liao, B.; Liu, Y.; Li, R.; Zhu, W. Coronavirus phylogeny based on triplets of nucleic acids bases. Chem. Phys. Lett. 2006, 421, 313-318. [CrossRef]
58. Ghosh, A.; Nandy, A.; Nandy, P. Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase. BMC Struct. Biol. 2010, 10. [CrossRef] [PubMed]
59. Ghosh, A.; Chattopadhyay, S.; Chawla-Sarkar, M.; Nandy, P.; Nandy, A. In silico study of rotavirus VP7 surface accessible conserved regions for antiviral drug/vaccine design. PLoS ONE 2012, 7, e40749. [CrossRef] [PubMed]
60. Sarkar, T.; Das, S.; De, A.; Nandy, P.; Chattopadhyay, S.; Chawla-Sarkar, M.; Nandy, A. H7N9 influenza outbreak in China 2013: In silico analyses of conserved segments of the hemagglutinin as a basis for the selection of peptide vaccine targets. Comput. Biol. Chem. 2015, 59, 8-15. [CrossRef] [PubMed]
61. Hawkins, D. M.; Basak, S. C.; Kraker, J.; Geiss, K. T.; Witzmann, F. A. Combining chemodescriptors and biodescriptors in quantitative structure-activity relationship modeling. J. Chem. Inf. Model. 2006, 46, 9-16. [CrossRef] [PubMed]
62. Basak, S. C.; Mills, D.; Gute, B. D.; Natarajan, R. Predicting pharmacological and toxicological activity of heterocyclic compounds using QSAR and molecular modeling. In QSAR and Molecular Modeling Studies of Heterocyclic Drugs, I; Gupta, S. P., Ed.; Springer-Verlag: Berlin, Germany; Heidelberg, Germany; New York, NY, USA, 2006; pp. 39-80.
63. Gonzalez-Diaz, H.; Gonzalez-Diaz, Y.; Santana, L.; Ubeira, F. M.; Uriarte, E. Proteomics, networks and connectivity indices. Proteomics 2008, 8, 750-778. [CrossRef] [PubMed]
64. Gonzalez-Diaz, H.; Perez-Montoto, L. G.; Duardo-Sanchez, A.; Paniagua, E.; Vazquez-Prieto, S.; Vilas, R.; Dea-Ayuelac, M. A.; Bolas-Fernándezd, F.; Munteanue, C. R.; Doradoe, J.; et al. Generalized lattice graphs for 2D-visualization of biological information. J. Theor. Biol. 2009, 261, 136-147. [CrossRef] [PubMed]
65. Vilar, S.; González-Díaz, H. QSPR models for human Rhinovirus surface networks. In Topological Indices for Medicinal Chemistry, Biology, Parasitology, Neurological and Social Networks; González-Díaz, H., Munteanu, C. R., Eds.; Transworld Research Network: Kerala, India; 2010; pp. 145-161.
66. Almeida, J. P.; Lin, A. Y.; Figueroa, E. R.; Foster, A. E.; Drezek, R. A. In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. Small 2015, 11, 1453-1459. [CrossRef] [PubMed]